Skip to main content
OpenTrials
Completed

NCT Number: NCT05157321

Repetitive Transcranial Magnetic Stimulation in Essential Tremors Patients

The aim of the study is to investigate the Effect of Repetitive Transcranial Magnetic Stimulation on Essential Tremors.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Al-Azhar university

Cairo, Egypt

About this study

Prior to start of rTMS sessions, Clinical evaluation and scaling of tremors using the ET rating scale (Fahn, Tolosa, Marin Tremor Rating Scale) will be employed on the participants in both groups.

rTMS frequency of 1Hz will be delivered to each of the participants in both groups. Each session will be administered once daily for 3 days a week for 4 weeks. 1200 pulses (30 pulses per train with total 40 trains having inter-train delay of 3 seconds) per session will be provided with the coil placed on both cerebellar hemispheres. rTMS frequency of 1Hz was kept constant based on previous studies.

rTMS sessions will be administered by trained professionals who was kept blinded to the research protocols used in the study. After completion of therapeutic programs (after 4 weeks), the participants will be asked to undergo post assessment of Fahn, Tolosa, Marin Tremor Rating Scale at the end of last rTMS session, 1 month, 3 months later.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient diagnosed with Essential tremors or Essential tremors plus based on the movement disorders consensus criteria(appendix 1)
  • Patient should have significant residual tremors despite of using appropriate medical treatment.
  • Age: patient should be above 18 years old.
  • Gender: males and females.

Exclusion criteria

  • Patients with history of seizures.
  • Patient receiving tremor active drugs including:
  • Central cholinergic drugs (acetylcholine chloride, muscarinic and nicotinic agonists, anticholinesterases, and aminopropranolols)
  • Central monoaminergic drugs (neuroleptics, phenylethylamines, and indoles)
  • Peripheral adrenergic drugs (lithium carbonate, amphetamine sulfate, adrenocorticosteroids, and thyroid hormone supplements)
  • Anticonvulsants (valproic acid), bronchodilators (theophylline and terbutaline sulfate)
  • Antidepressants (amitriptyline hydrochloride).
  • patients who have metal or electronic device implanted in their body such as :
  • cardiac peace maker
  • Aneurysm clips or coils
  • Stents in the neck or brain
  • Deep brain stimulators
  • Spinal cord stimulators
  • Electrodes to monitor brain activity
  • Metallic implants in ears and eyes
  • Bullet fragments in or near the head
  • Baclofen pumps
  • Other metal devices or object implanted in or near the head

Treatment and study plan

repetitive transcranial magnetic stimulation

Device

TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.

Sham repetitive transcranial magnetic stimulation

Device

Sham Repetitive Transcranial Magnetic Stimulation

Primary outcomes

  1. change in severity of essential tremors

    Time frame: 1 day, 1 month, and 3 months following the end of treatment.

    Fahn, Tolosa, Marin Tremor Rating Scale

Sponsors and collaborators

Lead sponsor

Al-Azhar University

Other

Registry information

Official study title

Effect of Repetitive Transcranial Magnetic Stimulation on Essential Tremors

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 15, 2021
Registry last updated
May 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.